36 results found.

Mixed Muellerian Cancer, Cervical Cancer, Ovarian Cancer, Breast Clinical Trial using Carboplatin; Olaparib; Treatment Effect

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Pharmacokinetic/Pharmacodynamic Study With a Phase I Run-In With a PARP Inhibitor (Olaparib) in Combination With Carboplatin for Refractory or Recurrent Women's Cancers.
Carboplatin; Olaparib; Treatment Effect

Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Ca Clinical Trial using fulvestrant; anastrozole

Alliance for Clinical Trials in Oncology - Recruiting 18 years or older.
- Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study.
fulvestrant; anastrozole

Breast Cancer Clinical Trial using GDC-0941; Placebo; paclitaxel

Genentech - Recruiting 18 years or older.
- A Phase II, Randomized Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer.
GDC-0941; Placebo; paclitaxel

Breast Cancer Clinical Trial using GDC-0032; Docetaxel; Paclitaxel

Genentech - Recruiting 18 years or older.
- A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination With Either Docetaxel or Paclitaxel in Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer.
GDC-0032; Docetaxel; Paclitaxel

HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Br Clinical Trial using laboratory biomarker analysis; pharmacological study; questionnaire administration; fluorine F 18-clevudine; positron emission tomography/computed tomography

University of Southern California - Recruiting 18 years or older.
- Development of an In Vivo Cell Proliferation Marker for PET Assessment of Chemotherapeutic Response in Cancer.
laboratory biomarker analysis; pharmacological study; questionnaire administration; fluorine F 18-clevudine; positron emission tomography/computed tomography

Breast Cancer Clinical Trial using Capecitabine; Exemestane; Everolimus

Novartis - Recruiting 18 years or older.
- Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in the Treatment of Postmenopausal Women With ER+Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole..
Capecitabine; Exemestane; Everolimus

Breast Cancer Clinical Trial using taxane; pertuzumab; trastuzumab [Herceptin]

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multicenter, Open-label, Single-arm Study of a Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer.
taxane; pertuzumab; trastuzumab [Herceptin]

Ductal Breast Carcinoma in Situ, Invasive Ductal Breast Carcinoma Clinical Trial using Behavioral dietary intervention; Therapeutic conventional surgery; Radiation therapy; Counseling intervention; Quality-of-life assessment

Thomas Jefferson University - Recruiting 18 years or older.
- A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients.
Behavioral dietary intervention; Therapeutic conventional surgery; Radiation therapy; Counseling intervention; Quality-of-life assessment

Breast Cancer Metastatic Clinical Trial using PF-03084014; Docetaxel

Pfizer - Recruiting 18 years or older.
- Phase 1B Study Of Docetaxel + PF-03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer.
PF-03084014; Docetaxel

Male Breast Cancer, Recurrent Breast Cancer, or Stage IV Breast C Clinical Trial using eribulin mesylate; laboratory biomarker analysis

University of Washington - Recruiting 18 years or older.
- Phase II Trial of Metronomic Eribulin (Halaven) In Pretreated Metastatic Breast Cancer (MBC).
eribulin mesylate; laboratory biomarker analysis

Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Ca Clinical Trial using veliparib; pegylated liposomal doxorubicin hydrochloride; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Study of ABT-888, PARP Inhibitor, and Pegylated Liposomal Doxorubicin (PLD) in Recurrent Gynecologic Cancer and Breast Cancer.
veliparib; pegylated liposomal doxorubicin hydrochloride; pharmacological study; laboratory biomarker analysis

Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Clinical Trial using cisplatin; laboratory biomarker analysis; pharmacological study; dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI; GDC -0941

Vanderbilt-Ingram Cancer Center - Recruiting 18 years or older.
- A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer.
cisplatin; laboratory biomarker analysis; pharmacological study; dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI; GDC -0941

BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Recurrent Breast Clinical Trial using veliparib; carboplatin; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of Single Agent ABT-888 With Post-Progression Therapy of ABT-888 in Combination With Carboplatin in Patients With Stage IV BRCA-associated Breast Cancer.
veliparib; carboplatin; laboratory biomarker analysis

Male Breast Cancer, Recurrent Breast Cancer, or Stage IV Breast C Clinical Trial using paclitaxel albumin-stabilized nanoparticle formulation; questionnaire administration

City of Hope Medical Center - Recruiting 65 years or older.
- Efficacy and Tolerability of Nanoparticle Albumin Bound Paclitaxel (Abraxane) in Patients 65 and Older With Metastatic Breast Cancer.
paclitaxel albumin-stabilized nanoparticle formulation; questionnaire administration

Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complic Clinical Trial using anastrozole; questionnaire administration; laboratory biomarker analysis; pharmacogenomic studies

Eastern Cooperative Oncology Group - Recruiting 18 years or older.
- A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS).
anastrozole; questionnaire administration; laboratory biomarker analysis; pharmacogenomic studies

Ovarian Cancer, or Breast Cancer Clinical Trial using BKM120 and Olaparib

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer.
BKM120 and Olaparib

Recurrent Breast Cancer, or Metastatic Breast Cancer Clinical Trial using Ruxolitinib; Paclitaxel

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- Phase II Study of Combination Ruxolitinib (INCB018242) With Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer Following Completion of a Phase I Combination Study in Recurrent/Metastatic Breast Cancer.
Ruxolitinib; Paclitaxel

Male Breast Cancer, Recurrent Melanoma, Stage IV Breast Cancer, S Clinical Trial using propranolol hydrochloride; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Pilot Study of Beta-Blockers in Patients With Advanced Cancer.
propranolol hydrochloride; Correlative Studies

Male Breast Cancer, Recurrent Breast Cancer, Recurrent Fallopian Clinical Trial using mifepristone; carboplatin; gemcitabine hydrochloride; laboratory biomarker analysis; pharmacological study

University of Chicago - Recruiting 18 years or older.
- Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer.
mifepristone; carboplatin; gemcitabine hydrochloride; laboratory biomarker analysis; pharmacological study

Primary Breast Cancer, or Recurrent/Metastatic Breast Cancer Clinical Trial

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting 18 years or older.
- Breast Cancer Proteomics and Molecular Heterogeneity.

Breast Cancer, Newly Diagnosed Breast Cancer, or Recurrent Breast Clinical Trial

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting 18 years or older.
- Circulating miRNAs: Novel Breast Cancer Biomarkers and Their Use for Guiding and Monitoring Response to Chemotherapy.

HER2-positive Breast Cancer, Recurrent Breast Cancer, or Stage IV Clinical Trial using pertuzumab; trastuzumab; paclitaxel albumin-stabilized nanoparticle formulation; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 19 years or older.
- Phase II Prospective Open Label Single Arm Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Metastatic Breast Cancer.
pertuzumab; trastuzumab; paclitaxel albumin-stabilized nanoparticle formulation; laboratory biomarker analysis

HER2-positive Breast Cancer, Inflammatory Breast Cancer, Male Bre Clinical Trial using entinostat; lapatinib ditosylate; trastuzumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I and Phase I Trastuzumab Cohort Study of Entinostat, Lapatinib and Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab Has Failed.
entinostat; lapatinib ditosylate; trastuzumab; laboratory biomarker analysis

Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Ca Clinical Trial using veliparib; cisplatin; vinorelbine tartrate; laboratory biomarker analysis; pharmacological study

University of Washington - Recruiting 18 years or older.
- Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer.
veliparib; cisplatin; vinorelbine tartrate; laboratory biomarker analysis; pharmacological study

Brain Metastases, Lung Cancer, Breast Cancer, Melanoma, or Malign Clinical Trial using 2B3-101; Trastuzumab; 2B3-101 60 mg/m2 every 4 weeks; 2B3-101 50 mg/m2 every 3 weeks

to-BBB technologies B.V. - Recruiting 18 years or older.
- An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma..
2B3-101; Trastuzumab; 2B3-101 60 mg/m2 every 4 weeks; 2B3-101 50 mg/m2 every 3 weeks

Breast Cancer Clinical Trial using ThermoDox in combination with Microwave Hyperthermia (heat)

Celsion - Recruiting 18 years or older.
- A Phase I/II Study Evaluating the Maximum Tolerated Dose, Bioequivalence/Pharmacokinetics, Safety, and Efficacy of Hyperthermia and ThermoDox (Lyso-Thermosensitive Liposomal Doxorubucin) in Patients With Local-Regional Recurrent Breast Cancer..
ThermoDox in combination with Microwave Hyperthermia (heat)

Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-posit Clinical Trial using veliparib; paclitaxel; carboplatin; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Advanced Solid Tumors.
veliparib; paclitaxel; carboplatin; pharmacological study; laboratory biomarker analysis

Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Ca Clinical Trial using dinaciclib; epirubicin hydrochloride; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study With Dose Expansion of Dinaciclib (SCH 727965) in Combination With Epirubicin in Patients With Metastatic Triple Negative Breast Cancer.
dinaciclib; epirubicin hydrochloride; laboratory biomarker analysis

Malignant Solid Tumour, Breast Cancer Nos Metastatic Recurrent, o Clinical Trial using Eribulin in Combination w/ Cyclophosphamide

University of California, San Francisco - Recruiting 18 years to 80 years.
- A Phase Ib/II Study of Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies.
Eribulin in Combination w/ Cyclophosphamide

Metastatic Breast Cancer Clinical Trial using TRC105

Tracon Pharmaceuticals Inc. - Recruiting 18 years or older.
- An Open Label Phase 1B Dose-Finding Study of TRC105 in Combination With Capecitabine for Progressive or Recurrent Metastatic Breast Cancer.
TRC105

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Clinical Trial using Fludarabine; Cyclophosphamide; Cyclosporine; Natural killer cells; IL-2; Methylprednisolone; Interleukin-2

Masonic Cancer Center, University of Minnesota - Recruiting 18 years or older.
- Lymphodepleting Chemotherapy and T-Cell Suppression Followed By Allogeneic Natural Killer Cells and IL-2 in Patients With Recurrent Ovarian, Fallopian Tube, Primary Peritoneal Cancer and Advanced Metastatic Breast Cancer (MT2009-30).
Fludarabine; Cyclophosphamide; Cyclosporine; Natural killer cells; IL-2; Methylprednisolone; Interleukin-2

Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-p Clinical Trial using therapeutic estradiol; exemestane; laboratory biomarker analysis; enzyme-linked immunosorbent assay

University of Arizona - Recruiting N/A or older.
- A Pilot Study Of Estradiol Followed By Exemestane For Post-Menopausal Hormone Receptor Positive Metastatic Breast Cancer After Prior Failed Endocrine Therapy: Reversing Endocrine Resistance.
therapeutic estradiol; exemestane; laboratory biomarker analysis; enzyme-linked immunosorbent assay

Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Ca Clinical Trial using mifepristone; placebo; nab-paclitaxel

University of Chicago - Recruiting 18 years or older.
- A Randomized Phase I Trial of Nanoparticle Albumin Bound Paclitaxel (Nab-paclitaxel, Abraxane) With or Without Mifepristone for Advanced Breast Cancer.
mifepristone; placebo; nab-paclitaxel

Breast Cancer Nos Metastatic Recurrent Clinical Trial using NK105; Paclitaxel

Nippon Kayaku Co.,Ltd. - Recruiting 20 years to 74 years.
- A Multi-national Phase III Clinical Study Comparing NK105 Versus Paclitaxel in Patients With Metastatic or Recurrent Breast Cancer.
NK105; Paclitaxel

Advanced/Recurrent Breast Cancer, Endometrial Cancer, or Ovarian Clinical Trial using Temsirolimus/PLD

Radboud University - Recruiting 18 years or older.
- A Phase Ib Study of Combination of Temsirolimus (Toriselr) and Pegylated Liposomal Doxorubicin (PLD, Doxilr/ Caelyxr) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer.
Temsirolimus/PLD